Microbiology: Current Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Microbiology: Current Research (2025) Volume 9, Issue 2

Hijacking the Host: Mechanisms of Bacterial Manipulation of Eukaryotic Cell Signaling

Ivan Petrov *

Department of Microbiology, University of California, USA

*Corresponding Author:
Ivan Petrov
Department of Microbiology,
, University of California, USA
E-mail: ivan.petrov@email.com

Received: 04-Apr-2025, Manuscript No. AAMCR-25-171236; Editor assigned: 05-Apr-2025, PreQC No. AAMCR-25-171236(PQ); Reviewed: 19-Apr-2025, QC No. AAMCR-25-171236; Revised: 23-Apr-2025, Manuscript No. AAMCR-25-171236(R); Published: 30-Apr-2025, DOI:10.35841/AAMCR-9.2.256

Citation: Petrov I. Hijacking the host: Mechanisms of bacterial manipulation of eukaryotic cell signaling. J Micro Bio Curr Res. 2025;9(2):256

Visit for more related articles at Microbiology: Current Research

Introduction

Pathogenic bacteria have evolved sophisticated strategies to manipulate host cell signaling pathways, enabling them to invade, survive, and proliferate within eukaryotic cells. This manipulation is central to microbial pathogenesis and involves a complex interplay between bacterial effector proteins and host cellular machinery. Understanding these mechanisms not only sheds light on host-pathogen interactions but also opens avenues for therapeutic interventions. A cornerstone of bacterial manipulation is the use of specialized secretion systems, particularly Type III (T3SS) and Type IV (T4SS) secretion systems. These needle-like structures inject effector proteins directly into host cells, bypassing extracellular defenses. For example, Salmonella enterica and Shigella flexneri utilize T3SS to deliver proteins that modulate host cytoskeletal dynamics and vesicular trafficking [1].

One of the primary targets of bacterial effectors is the host cytoskeleton. Actin filaments and microtubules are manipulated to facilitate bacterial entry, intracellular movement, and immune evasion. Listeria monocytogenes uses the surface protein ActA to hijack host actin polymerization, propelling itself through the cytoplasm. Similarly, Rickettsia species exploit host microtubules for intracellular transport [2].

Bacterial pathogens often mimic or interfere with host signaling molecules. Effector proteins can activate or inhibit pathways such as MAPK, NF-κB, and PI3K/Akt, which are crucial for immune responses and cell survival. Yersinia species produce YopJ, an acetyltransferase that blocks MAPK and NF-κB signaling, suppressing inflammation and promoting bacterial survival. Intracellular bacteria must avoid lysosomal degradation. To achieve this, they manipulate vesicular trafficking to create specialized vacuoles. Legionella pneumophila forms the Legionella-containing vacuole (LCV) by recruiting ER-derived vesicles, mediated by the effector protein DrrA. Chlamydia trachomatis similarly remodels its inclusion to evade host defenses [3].

Some bacteria alter host gene expression through epigenetic mechanisms. Effectors can modify chromatin structure or interfere with transcription factors. Helicobacter pylori CagA protein interacts with host histone deacetylases, leading to changes in gene expression that favor bacterial persistence. Additionally, bacterial miRNA-like molecules can modulate host mRNA stability [4].

To persist within the host, bacteria must evade immune detection. Mycobacterium tuberculosis inhibits phagosome maturation and antigen presentation, while Brucella species suppress Toll-like receptor signaling. These strategies prevent the activation of innate and adaptive immune responses, allowing chronic infection. Manipulating host cell death pathways is another tactic. Bacteria can inhibit apoptosis to prolong their intracellular survival or induce necrosis to facilitate dissemination. Salmonella effectors such as AvrA inhibit apoptosis by stabilizing anti-apoptotic proteins. Conversely, Shigella triggers pyroptosis to escape from macrophages. Understanding these mechanisms has profound implications for drug development. Targeting bacterial effectors or their interactions with host proteins could lead to novel antimicrobial therapies. For instance, inhibitors of T3SS are being explored as antivirulence agents that disarm pathogens without killing them, potentially reducing selective pressure for resistance [5].

Conclusion

Bacterial manipulation of eukaryotic cell signaling is a multifaceted process involving secretion systems, effector proteins, and host-pathogen interactions at molecular and cellular levels. Continued research in cellular microbiology is essential to unravel these complex mechanisms and develop innovative strategies to combat infectious diseases.

References

  1. Forterre P. Defining life: the virus viewpoint. Orig Life Evol Biosph. 2010;40:151-60.

    2. Indexed at, Google Scholar, Cross Ref

  2. Koonin EV, Dolja VV. A virocentric perspective on the evolution of life. Curr Opin Virol. 2013;3(5):546-57.

    3. Indexed at, Google Scholar, Cross Ref

  3. Rohwer F, Thurber RV. Viruses manipulate the marine environment. Nature. 2009;459(7244):207-12.

    4. Indexed at, Google Scholar, Cross Ref

  4. Suttle CA. Marine viruses—major players in the global ecosystem. Nat Rev Microbiol. 2007;5(10):801-12.

    5. Indexed at, Google Scholar, Cross Ref

  5. Katzourakis A, Gifford RJ. Endogenous viral elements in animal genomes. PLoS Gen. 2010;6(11):e1001191.

    6. Indexed at, Google Scholar, Cross Ref

  6. Barr JJ, Auro R, Furlan M. Bacteriophage adhering to mucus provide a non–host-derived immunity. Proc Natl Acad Sci USA. 2013;110(26):10771-6.

    7. Indexed at, Google Scholar, Cross Ref

  7. Summers WC. The strange history of phage therapy. Bacteriophage. 2012;2(2):130-3.

    8. Indexed at, Google Scholar , Cross Ref

  8. Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res. 2021;11:748-87.

    9. Indexed at, Google Scholar, Cross Ref

  9. Gill JJ, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol. 2010;11(1):2-14.

    10. Indexed at, Google Scholar, Cross Ref

  10. Pires DP, Costa AR, Pinto G. Current challenges and future opportunities of phage therapy. FEMS. 2020;44(6):684-700.

    11. Indexed at, Google Scholar, Cross Ref

Get the App